Both NMN and NR raise NAD+. The question is which one does it better, and whether the research supports the price premium.
If you've spent any time in longevity or biohacking circles, you've run into this debate. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both NAD+ precursors, compounds that your body converts into NAD+, a coenzyme that's central to cellular energy production, DNA repair, and the function of enzymes associated with longevity. Both have legitimate research behind them. Both are sold at premium prices.
So which one should you take?
The honest answer is that the research is still evolving, but the weight of current evidence, particularly human clinical trial data, gives NMN a meaningful edge. Here's why we think that, and what the actual research says.
Why NAD+ matters in the first place
Before comparing NMN and NR, it's worth understanding why anyone cares about NAD+ at all.
NAD+ (nicotinamide adenine dinucleotide) is one of the most important molecules in your body. It's required for hundreds of enzymatic reactions, including the processes that generate ATP in your mitochondria and the repair of damaged DNA. It also activates a class of proteins called sirtuins, enzymes associated with longevity that regulate inflammation, stress response, and metabolic health.
Here's the problem: NAD+ levels decline significantly with age. Research shows levels fall substantially by middle age, with this decline associated with reduced cellular energy, increased inflammation, and various markers of biological aging. This is why researchers have been intensely interested in whether supplementing with NAD+ precursors can restore those levels and slow some of the downstream effects.
The challenge is that taking NAD+ directly is ineffective, as it doesn't survive digestion well enough to reach your cells in useful amounts. You need a precursor: a compound your body can absorb and convert. That's where NMN and NR come in.
The biochemical pathway: where they differ
NMN and NR sit at slightly different points in the NAD+ synthesis pathway.
NR (nicotinamide riboside) is converted to NMN first, and then NMN is converted to NAD+. So NR has one more conversion step to undergo before becoming NAD+. This doesn't make it ineffective; NR has been shown to raise NAD+ in humans. But it means NMN is one step closer to the end product.
NMN is directly upstream of NAD+ in the salvage pathway. Some research suggests NMN may be taken up more efficiently by certain tissues because cells have a specific transporter (Slc12a8) that facilitates direct NMN uptake, bypassing the NR-to-NMN conversion step. This transporter has been confirmed in mouse tissue and more recently hypothesized in human tissue, though this is still an active area of research.
Does this biochemical proximity to NAD+ translate into better outcomes in humans? That's the question the clinical evidence needs to answer.
What the human clinical research shows
NMN human trials
The evidence base for NMN in humans has grown substantially in recent years.
A key study published in Frontiers in Nutrition confirmed that oral NMN supplementation successfully and dose-dependently increases blood NAD+/NADH levels in healthy subjects, establishing that the mechanism works in humans, not just lab animals (Okabe K, et al., 2022). This was an important milestone because a lot of the earlier NMN excitement was based on impressive animal research that hadn't yet been replicated in humans.
A 12-week study in older Japanese adults found that NMN supplementation improved physical function, with improvements in muscle strength and endurance alongside increased NAD+ levels (Kim M, et al., Nutrients, 2022). A separate study found improvements in muscle function and blood NAD+ levels in healthy older men after 12 weeks of NMN supplementation, though the magnitude of physical performance improvements was modest (Igarashi M, et al., NPJ Aging, 2022).
Safety data is reassuring: studies using doses up to 1,200mg daily for 6 weeks and 900mg daily for 8 weeks have shown no adverse effects in humans. One study tested 2,000mg daily for 14 days with no safety signals.
NR human trials
NR has a longer track record in human research, as it was commercially available earlier and has more published trials. Studies using 250–1,000mg daily have consistently shown that NR raises blood NAD+ levels in humans, with effects appearing within 2–4 weeks.
However, a recurring limitation of NR research is the gap between raising NAD+ and demonstrating meaningful functional benefits. Multiple well-designed clinical trials have shown that NR successfully increases NAD+ levels but failed to show statistically significant improvements in the metabolic or physical performance outcomes researchers expected to see. The NAD+ goes up, but the downstream benefits in healthy, non-deficient adults have been harder to demonstrate.
This doesn't mean NR doesn't work; it may mean that the benefits are more pronounced in older adults, in those with genuine NAD+ deficiency, or over longer supplementation periods than most trials have examined.
Comparing the evidence directly
Here's what the comparison actually looks like when you put the research side by side:
NAD+ elevation: Both NMN and NR reliably increase blood NAD+ levels in human studies. Edge: roughly equivalent, though NMN's direct conversion pathway may produce faster elevation in some tissues.
Functional benefits in humans: NMN's recent trials have shown more consistent signals on physical function outcomes — muscle strength, endurance, and physical performance — particularly in older adults. NR trials have shown more inconsistent results on functional endpoints despite reliable NAD+ elevation. Slight edge: NMN.
Research volume: NR has more published human trials overall due to its earlier commercialization. NMN's human research has accelerated rapidly since 2020. Edge: NR on volume, but the gap is closing.
Safety: Both compounds have solid short-term safety profiles in human studies at common doses. Neither raises serious safety concerns at supplemental doses. Edge: comparable.
Dose efficiency: NMN tends to require a larger absolute dose to achieve comparable NAD+ elevation (commonly 250–500mg effective range for NR vs 300–600mg+ for NMN). This partially offsets the cost difference between the compounds.
A note on the NMN regulatory history
NMN spent a stretch in regulatory limbo in the United States after the FDA was asked to evaluate whether it should be classified as an investigational drug rather than a dietary supplement (following pharmaceutical investment in NMN-based therapeutics). That has since moved in NMN's favor: the FDA has acknowledged new dietary ingredient notifications for NMN, most recently in January 2026, when it acknowledged the notification for SIRTality® β-Nicotinamide Mononucleotide (NMN) (NDIN 1265), the NMN we use. An acknowledgment means the FDA filed the notification without objection; it is not an approval. NMN is currently marketed as a dietary ingredient in the US. We track this closely and will say so plainly if the status changes.
What we use and why
RBRN Vitality Complex, our testosterone support and cellular energy formula, includes 500mg of SIRTality® β-Nicotinamide Mononucleotide (NMN), a substantial dose that aligns with the human research on NAD+ elevation and physical function benefits. We chose NMN over NR for two reasons: the direct biochemical pathway to NAD+ and the emerging clinical evidence on functional outcomes, particularly the 12-week studies showing improvements in muscle function in aging adults.
We'll be upfront about what the evidence does and doesn't show: NMN has strong evidence that it raises NAD+ in humans and promising but still early evidence for functional benefits. It's not a longevity miracle. It's an investment in cellular infrastructure that becomes increasingly relevant as NAD+ naturally declines with age. The research suggests this is a worthwhile bet, particularly for men over 35.
The bottom line
NMN and NR both work in the fundamental sense; they both raise NAD+ levels in humans. If you're choosing between them, NMN has a more direct biochemical pathway, a rapidly growing human evidence base, and more consistent functional outcomes in recent trials. NR has more total published research due to its earlier availability, but its functional benefits have been harder to demonstrate despite reliable NAD+ elevation.
Neither compound is snake oil. Both are legitimate tools for supporting cellular NAD+ levels. For men focused on energy, muscle function, and long-term vitality, the current evidence points to NMN as the more defensible choice.
Read the full research breakdown on NMN, including all cited studies.
See how NMN fits into the RBRN Vitality Complex formula.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. If you have a medical condition or take prescription medications, consult your healthcare provider before starting any supplement.
